Pandemic Perspectives
One year on from the World Health Organization declaring COVID-19 a global pandemic on 11 March 2020, editors across Informa Pharma Intelligence publications are taking a closer look at its impact and possible lasting implications for the biopharma and medtech industries.
From limited supplies and black marketing in the early days, to subdued sales as COVID-19 cases declined, and now back to a potential uptick in usage as infections surge, antivirals like remdesivir have had an eventful several months in India, mirroring the peaks and troughs of the devastating pandemic
Remdesivir in particular may have received varying global endorsement, but the recent surge in infections in many parts of the world, including India, could imply that Gilead Sciences, Inc.’s blockbuster antiviral remains an important part of the treatment arsenal, as well as a revenue generator for its numerous Indian licensees, despite the pick-up in global vaccination efforts
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?